OK after reading the presentation and some of the comments on various threads.
The tension. Some people are saying... "If CF33/Vaccinia works why would they buy a complementary asset for so much!" Others are saying, well "if CF33 results are great (expected November a bit later) why do a CR now? wait and get a better SP appreciation". There does seem to be genuine tension here. Think about it, If CF33 is a blockbuster and the Vaccinia trials are
that good, this CR seems incomprehensible. But also it just seems so stupid to buy more if the Vaccinia trials are
tanking. But what about the following scenario?
Vaccinia - good safety, underwhelming efficacy? What if the vaccinia trials are neither shooting the lights out, nor tanking?
What if the results are good safety profile, (moving through cohorts), but with a little bit of efficacy (or may be not much - not enough to get excited). Vaccinia results - so-so
What will happen next 12 months? Probably stagnationSo in their strategy forward planning meeting IMU think through, what happens next? When the results for vaxxinia/CF33 come out later this year, (say Nov/Early 24) how will the market respond? Probably not that great, where that leave us mid later 24? Stagnant.
Enter Oncarlytics (ace up the sleeve?) But hang on we have the Oncarlytics card up our sleeve!!
Yes but that is Preclinical, we will file the IND end of this year but we really wont have results maybe another 18 even 24 months.
+ with oncarlytics we are dependant on our partners, we have been waiting and waiting and waiting on them, after all, what is happening with our partners Estrella/Eureka or Cellularity lately, it has been over two years ago!!.
What do we do? Killing two birds with one stone. Well we strike now while we can. We know that CF33 works kinda OK, but will be supercharged with the added potency of a CD19- CarT. We have been looking at these Car-T companies as possible acquisitions (with a view this may happen a year or so down the track)> Let's raise now, it will get us through the next 12 months (after the dust settles with CF33 results) + we get our hands on a CD19 Car-T, we can then drive the Car-t + oncaryltics through for the next 12-18 months and we will in a better position by end of 24 start of 25.
DYOR and all that.
(20min delay)